Psoriasis drug safety under the microscope: thousands enrolled in Real-World study
NCT ID NCT03254667
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tracks 3,500 adults with moderate-to-severe psoriasis to compare the long-term safety of the drug brodalumab against other psoriasis treatments. Participants are already taking or switching to a systemic therapy as part of their normal care. The main goal is to see how many people develop cancer (excluding common skin cancers) while on brodalumab versus other biologic medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Registry
Bridgewater, New Jersey, 08807, United States
Conditions
Explore the condition pages connected to this study.